Importance of Dose Intensity in Treatment of Advanced Non-small Cell Lung Cancer in the Elderly

Overview

Journal South Asian J Cancer

Specialty Oncology

Date 2014 Jan 24

PMID 24455502

Citations 3

Authors

Narayanan Prasad

Ashish Bakshi

Chetan Deshmukh

Sachin Hingmire

Aa Ranade

Purvish Parikh

Affiliations

Soon will be listed here.

Abstract

Maintaining appropriate dose intensity is important not only in the curative setting but also in treatment with palliative intent. We evaluated the outcome of advanced non small cell lung cancer treated with doublet platinum based chemotherapy. Outcome was compared between patients treated by medical oncologists at a tertiary cancer center and those treated by non medical oncologists in the community. The dose intensity, overall response rate and overall survival was significantly better when patients were treated by trained qualified and experienced medical oncologists. Hence, even in the palliative setting, cancer directed systemic therapy will yield maximum benefit for the patients when treated by medical oncologists.

Citing Articles

Uniqueness of lung cancer in Southeast Asia.

Noronha V, Budukh A, Chaturvedi P, Anne S, Punjabi A, Bhaskar M Lancet Reg Health Southeast Asia. 2024; 27:100430.

PMID: 39157507 PMC: 11328770. DOI: 10.1016/j.lansea.2024.100430.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S Support Care Cancer. 2017; 25(11):3295-3304.

PMID: 28842778 PMC: 5610660. DOI: 10.1007/s00520-017-3842-1.

Lung cancer in the Indian subcontinent.

Noronha V, Pinninti R, Patil V, Joshi A, Prabhash K South Asian J Cancer. 2016; 5(3):95-103.

PMID: 27606290 PMC: 4991146. DOI: 10.4103/2278-330X.187571.

References

Brown J, Eraut D, Trask C, Davison A . Age and the treatment of lung cancer. Thorax. 1996; 51(6):564-8. PMC: 1090483. DOI: 10.1136/thx.51.6.564. View

Mandrekar S, Schild S, Hillman S, Allen K, Marks R, Mailliard J . A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006; 107(4):781-92. DOI: 10.1002/cncr.22049. View

Abratt R, Bezwoda W, FALKSON G, Goedhals L, Hacking D, Rugg T . Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994; 12(8):1535-40. DOI: 10.1200/JCO.1994.12.8.1535. View

Yancik R, Ries L . Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000; 14(1):17-23. DOI: 10.1016/s0889-8588(05)70275-6. View

Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M . An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2004; 46(1):61-76. DOI: 10.1016/j.lungcan.2004.02.018. View

Tibaldi C, Bernardini I, Chella A, Russo F, Toma G, Tempestini F . Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. Lung Cancer. 2005; 51(2):217-23. DOI: 10.1016/j.lungcan.2005.10.013. View

Stinchcombe T, Socinski M . Drug development in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol. 2004; 31(6 Suppl 11):21-6. DOI: 10.1053/j.seminoncol.2004.10.005. View

Gatzemeier U, Shepherd F, Le Chevalier T, Weynants P, Cottier B, Groen H . Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996; 32A(2):243-8. DOI: 10.1016/0959-8049(95)00444-0. View

. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311(7010):899-909. PMC: 2550915. View

10.

Cattel L, Airoldi M, Delprino L, Passera R, Milla P, Pedani F . Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol. 2006; 17 Suppl 5:v142-7. DOI: 10.1093/annonc/mdj970. View

11.

Hespanhol V, Queiroga H, Magalhaes A, Santos A, Coelho M, Marques A . Survival predictors in advanced non-small cell lung cancer. Lung Cancer. 1995; 13(3):253-67. DOI: 10.1016/0169-5002(95)00497-1. View

12.

Hutchins L, Unger J, Crowley J, COLTMAN Jr C, Albain K . Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341(27):2061-7. DOI: 10.1056/NEJM199912303412706. View

13.

Vercelli M, Quaglia A, Casella C, Mangone L . Cancer patient survival in the elderly in Italy. ITACARE Working Group. Tumori. 1997; 83(1):490-6. DOI: 10.1177/030089169708300111. View

14.

Stanley K . Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980; 65(1):25-32. View

15.

Xu N, Shen P, Zhang X, Yu L, Bao H, Shi G . Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2006; 59(1):1-7. DOI: 10.1007/s00280-006-0237-2. View

16.

Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M . Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs. 2005; 16(10):1129-34. DOI: 10.1097/00001813-200511000-00013. View